Pulmonary hypertension drug PulmoLAR in human trial
Human trials on a new treatment for pulmonary arterial hypertension have started.
BY OUR PHARMA CORRESPONDENT
April 2, 2006
Human trials on a new treatment for pulmonary arterial hypertension have started, informed PR Pharmaceuticals, Inc. (PRP), in a news release.
The double-blind, placebo-controlled phase 1 clinical study is designed to assess the safety, tolerability and pharmacokinetics of a subcutaneous injection of 2-methoxyestradiol – 2ME in healthy volunteers.
The drug named PulmoLAR has multiple mechanisms of action, many of which are relevant to pulmonary arterial hypertension (PAH). In vitro studies have demonstrated 2ME reduces endothelial cell production of endothelin-1 and increases synthesis of prostacyclin. 2ME is also a potent antiproliferative agent. PulmoLAR is PRP’s proprietary sustained-release injectable formulation.
PRP is a biopharmaceutical company developing, manufacturing and commercializing bioactive compounds in its injectable sustained-release technologies. PRP is applying compelling and patented technology to create a diverse range of candidate pharmaceutical products to address unmet medical needs.